Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
08. Januar 2025 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
17. Dezember 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
NeuroAge Therapeutics: Revolutionary Brain Health Test Predicts Dementia Risk 30 Years in Advance
25. November 2024 21:01 ET
|
NeuroAge Therapeutics
NeuroAge Therapeutics launches the NeuroAge Test, a cutting-edge tool predicting dementia risk 30 years early to optimize brain health
Allyx Therapeutics Awarded $3.3 Million NIH Grant to Support Further Clinical Studies of Lead Candidate ALX-001
15. Oktober 2024 07:05 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics has been awarded a $3.3 million grant as part of the NIH's Small Business Innovation Research Commercial Readiness Pilot program
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
19. September 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Tiziana Receives $3.4 Million in Non-Dilutive Funding
28. Juni 2024 11:01 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative...
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
26. Juni 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
11. Juni 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
11. Juni 2024 08:00 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
28. Mai 2024 08:00 ET
|
Neurona Therapeutics
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference